Seres Therapeutics, Inc. MCRB
3.52
(0.10)
(2.76%)
as of 25 Sep
- Market cap
- $36.0M
- P/E
- 0.0×
Follow MCRB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
15.95% | 19.64% | (121.87%) | (66.57%) | |
| 3.35% | 4.10% | (33.29%) | (18.31%) | ||
ROIC |
0.00% | 0.00% | 0.00% | (277.30%) | |
Return on Tangible Assets |
14.32% | 15.11% | (242.41%) | (79.90%) | |
Average Days of Receivables |
2.22 | 128.11 | 55.91 | 4,899.10 | |
Free Cash Flow per Share |
(2.67) | 0.12 | (4.40) | (5.28) | |
Free Cash Flow |
(23.37) | 1.08 | (42.15) | (51.25) | |
Capital Expenditures |
(0.31) | (0.04) | — | 0.01 | |
Piotroski F-Score |
5.00 | 4.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(25.24%) | 1.24% | (74.83%) | (102.25%) | |
Accounts Receivable Turnover |
13.16 | 1.14 | 1.02 | 0.14 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
39.38% | 3,330.62% | 3,315.84% | 2,476.69% | |
Selling, General and Administrative Expense of Revenue |
34.57% | 2,658.25% | 2,323.34% | 1,707.17% | |
Share Based Compensation of Revenue |
8.95% | 735.91% | 643.46% | 487.84% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
(4.27) | 0.20 | 0.90 | 2.28 | |
Depreciation/Fixed assets |
0.50 | 0.54 | 0.56 | 0.59 | |
Capex/Depreciation |
(0.07) | (0.01) | 0.00 | 0.00 | |
Revenue per Share |
14.56 | 0.17 | 0.16 | 0.19 | |
Operating CF per Share |
(2.63) | 0.13 | (4.40) | (5.28) | |
Capex per Share |
(0.04) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.03 | 0.00 | 0.00 | |
Net Profit Margin |
4.23% | 386.69% | (3,083.43%) | (1,192.94%) |
Columns are period end dates